Aniko Gal

Dr. Aniko Gal

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2018 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
NKNóra Kecskeméti
Nóra Kecskeméti
MSMagdolna Szönyi
Magdolna Szönyi
AGAnita Gáborján
Anita Gáborján
MKMarianna Küstel
Marianna Küstel
GMGyörgy Máté Milley
György Máté Milley
AGAniko Gal
Aniko Gal

31 May 2021 in Life
Verified
Journal Article
Open access
PDF file
AGAniko Gal
Aniko Gal
ZGZoltán Grosz
Zoltán Grosz
BBBeáta Borsos
Beáta Borsos
ISIldikó Szatmári
Ildikó Szatmári
ASAgnes Sebők
Agnes Sebők
MMMaria Judit Molnar
Maria Judit Molnar
Pompe disease is caused by the accumulation of glycogen in the lysosomes due to a deficiency of the lysosomal acid-α-glucosidase (GAA) enzyme. Depending on residual enzyme activity, the disease manifests two distinct phenotypes. In this study, we assess an enzymatic and genetic analysis of Hungarian patients with Pompe disease. Twenty-four patients diagnosed with Pompe disease were included. Enzyme activity of acid-α-glucosidase was measured by mass spectrometry. Sanger sequencing and an MLPA of the GAA gene were performed in all patients. Twenty (83.33%) patients were classified as having late-onset Pompe disease and four (16.66%) had infantile-onset Pompe disease. Fifteen different pathogenic GAA variants were detected. The most common finding was the c.-32-13 T > G splice site alteration. Comparing the α-glucosidase enzyme activity of homozygous cases to the compound heterozygous cases of the c.-32-13 T > G disease-causing variant, the mean GAA activity in homozygous cases was significantly higher. The lowest enzyme activity was found in cases where the c.-32-13 T > G variant was not present. The localization of the identified sequence variations in regions encoding the crucial protein domains of GAA correlates with severe effects on enzyme activity. A better understanding of the impact of pathogenic gene variations may help earlier initiation of enzyme replacement therapy (ERT) if subtle symptoms occur. Further information on the effect of GAA gene variation on the efficacy of treatment and the extent of immune response to ERT would be of importance for optimal disease management and designing effective treatment plans.

30 November 2011
Verified
Journal Article
Closed access
IVIldikó Vastagh
Ildikó Vastagh
AGAniko Gal
Aniko Gal
VRViktória Reményi
Viktória Reményi
JSJudit Semjén
Judit Semjén
TLTímea Lukács
Tímea Lukács
MMMaria Judit Molnar
Maria Judit Molnar